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Calmodulin (CaM) is one of the intracellular calcium binding
proteins which regulates the functions of proteins and
enzymes associated with various cellular processes (for review
Klee & Newton, 1985; Cohen, 1988). CaM has been demon-
strated to regulate cyclic nucleotide metabolism (Brostrom et
al., 1975), mitosis, cell cycle progression (Rasmussen &
Means, 1989) and phosphorylation of oestrogen receptor
(ER) (Migliaccio et al., 1984). It has also been reported that
oestrogens influence the synthesis of CaM in the rabbit
myometrium (Matsui et al., 1983) and in rat and human uteri
(Yoshida et al., 1985). Since human breast cancer is a good
model in which to study hormonal influences, the present
study was planned to investigate the relationship, if any,
between oestradiol-17, (E2), ER and CaM concentrations.
ER assay
Tumour tissue weighing 500 mg was washed, minced finely
and homogenised in three volumes of 10 mM Tris buffer,
pH 7.4, containing 1.5 mM EDTA, 5 mM 2-mercaptoethanol,
12 mM thioglycerol and 20% glycerol, using polytron pt-10
homogeniser in an ice bath. Cytosol was prepared by centri-
fuging the homogenate at 105,000 g for 1 h at 4°C and used
for ER and E2 measurement. ER concentration in the
tumour tissue cytosol was measured by saturation analysis.
0.2 ml of cytosol containing 1 mg protein was incubated
overnight at 4°C with varying concentrations (0.2-20 nM) of
[2,4,6,7-3H]-Oestradiol (specific activity 110 Ci mmol-',
Amersham International plc, UK), and in the presence or
absence of 100 fold excess of radioinert E2. A ten-fold excess
of 5-dihydrotestosterone was added in all samples to elimin-
ate any binding contribution from androgen receptor. Bound
and free E2 from the reaction mixture was separated by
addition of dextran-coated charcoal. The bound labelled E2
in the supernatant was measured by liquid scintillation
counter. The concentration of ER was determined by Scat-
chard analysis (McGuire et al., 1975).
E2 assay
E2 from the cytosol was extracted with ether and separated
on a Sephadex LH-20 column equilibrated with benzene:
methanol (85:15 v/v) according to the method of Verdonck
and Vermeulen (1974) and E2 was measured by radio-
immunoassay using antisera against E2. The recovery of
oestrodiol by the extraction procedure varied from 84 to
90%. E2 antisera was raised in rabbit against 17,-oestradiol-
3-(o-carboxymethyl)-ether-BSA conjugate. The cross reactiv-
ity of E2 antisera was 1.25% with testosterone, 2.7% with
16-epioestriol and less than 1% with progesterone, cortisol,
dehydroepiandrosterone, androsterone, 5'-dihydrotesto-
sterone, oestrone and oestriol as tested by radioimmuno-
assay. The intra and interassay coefficients of variation
ranged between 2-4% and 10-15% respectively.
CaM assay
For CaM assay, the tissue extract was prepared according to
Wei and Hickie (1981) with minor modifications. The tissue
was homogenised in three volumes of Tris-HCl pH 6.8
(buffer-A), consisting of 60 mM Tris-HCI and 1 mM EGTA
and the supernatant was prepared by centrifuging the homo-
genate at 105,000 g for 1 h at 4°C. The pellet was rehomo-
genised with three volumes of buffer-A and the supernatant
was prepared as described above. The supernatants from the
first and second centrifugation were pooled and used for the
assay of CaM in the soluble fraction. To assay the CaM in
the particulate fraction, the pellet was homogenised in three
volumes of buffer-B, consisting of buffer-A and 2% Triton-X
100. The homogenate was left at 4°C for 2 h and stirred
intermittently. The supernatant was prepared by centrifuging
the homogenate at 105,000 g for 1 h at 4°C. The pellet was
rehomogenised with three volumes of buffer-B and the super-
natant was prepared as described above. The supernatants
from these two fractions were pooled and used for the assay.
CaM in the soluble and particulate fractions were assayed
according to the method of Veigl et al. (1984). Briefly, sam-
ples along with 100 ng of standard CaM (Purified bovine
brain CaM, Sigma Chemical Co, St. Louis, USA) was elec-
trophoresed on 1 mm thick, 15% polyacrylamide gels and
stained with silver nitrate (Morrissey, 1981) and the CaM
concentrations in the gel were quantitated densitometrically
on a Densican, Kipp and Zonen, Netherland.
The amount of CaM in the samples was calculated from
the CaM standard curve. Protein estimation was done ac-
cording to Lowry et al. (1951).
The concentrations of the cytosol E2, ER and CaM were
measured in 38 breast tumour tissues. In this study tumours
having ER content more than 10fmol mg-' cytosol protein
were considered as ER positive (ER') and those containing
less than that were considered as ER negative (ER-). Of the
38 cases studied 23 (61%) were ER' and 15 (39%) were ER-
tumours. In ER' tumours the median value of ER was
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Figure 1 Correlation of ER levels with calmodulin levels in ER+
breast tumours (r = 0.77, P<0.001, n = 23).
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17 fmol mg-' cytosol protein. E2 level in the ER' tumours
was significantly higher than the ER- tumours and is in
agreement with the findings of Fishman et al. (1977);
Maynard et al. (1978), and Drafta et al. (1983). The total
CaM concentration in ER' tumours was 2.4 times higher
than in the ER- tumours and the difference was statistically
significant (P<0.001, Table I). Correlation analysis was per-
formed in ER' tumours to understand whether any relation-
ship existed between ER and total CaM concentrations and
the results showed a significant positive correlation (Figure
1). In ER' and ER- tumours CaM levels were analysed in
the soluble and particulate fractions to understand the distri-
bution of CaM (Table I). In both ER' and ER- tumours the
major portion of CaM was seen in the soluble fraction
representing the cytosol. The soluble and particulate CaM
levels in ER' tumours were significantly higher than the
corresponding fractions in ER- tumours (P<0.001).
Though ER' tumours had higher concentrations of particu-
late CaM than the ER- tumours the mean ratio of particu-
late to the soluble CaM concentrations remained the same
(0.2, Table I). The menstrual status of the breast cancer
patients and the CaM levels in tumour tissues are shown in
Table II. Irrespective of menopausal status CaM level and E2
levels were higher in the ER' than the ER- tumours. In
conclusion, the increased E2 and CaM levels in the soluble
fraction and positive correlation between ER and CaM level
in ER' tumours suggest that in breast tumours CaM level is
influenced by ER. This is supported by the report that
administration of oestrogen to ovariectomised rabbits speci-
fically increased the cytosol CaM concentrations in the uterus
(Matsui et al., 1983). A similar finding was reported by
Yoshida et al. (1985) in rat and human uterus.
Table I Tissue E2 and CaM levels in ER' and ER- tumours
ER+ ER-
(n =23) (n = 15) *
E2 pgmg-'t 17.1±8.1 5.0±3.1 P<0.001
cytosol protein
CaM tLg mg-' proteint
Total 14.2±3.7 6.0±2.3 P<0.001
Soluble 12.1±3.9 4.9±2.1 P<0.001
Particulate 2.0±0.7 1.1 ±0.3 P<0.001
Particulate/soluble 0.2±0.2 0.2±0.8 NS
*Mann-Whitney test; NS = not significant; t Mean+s.d.; n = no. of
cases.
Table II Menopausal status and CaM levels
Menopausal E2 pg ml- 't CaM yig mg-'t
status cytosolprotein protein
ER+(7) 14.7±8.2 11.9±2.6
Pre
ER- (5) 6.8±3.7 6.4±1.0
ER+ (16) 16.6±+8.1 15.1±+3.9
Post
ER- (10) 4.0±2.4 5.7±2.7
Number of cases in parentheses. t Mean±s.d.
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